Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Revisiones de Libros, Música y Videos / / Referencia
Reviewer: Carolyn Vachani, MSN, RN, AOCN
OncoLink
Ultima Vez Modificado: 23 de febrero del 2003
Written by: The National Marrow Donor Program
Over the last 35 years, bone marrow and stem cell transplantation have moved from an experimental treatment to a widely accepted standard of care for many diseases. By the mid-1970s, the first unrelated donor transplant had been performed and physicians had learned the importance of HLA (human leukocyte antigen) matching in the success of these transplants. In 1979, Laura Graves was the first leukemia patient to undergo an unrelated donor transplant. Having experienced the difficulty of the search process back then, her family expressed the need for a donor registry. Their efforts, combined with those of other interested persons, prompted several states to form registries, but the need for a national database was evident. In 1984, with the encouragement of Mr. Graves and a group of physicians and families, Congress passed the National Organ Transplant Act, which included language to evaluate unrelated marrow transplantation and the feasibility of establishing a national donor registry. In July 1986 the National Marrow Donor Program (originally called the National Bone Marrow Donor Registry) was born.
The National Marrow Donor Program (NMDP) is an international network of transplant, donor, collection and apheresis centers and cord blood banks. The mission of the NMDP is to extend and improve life, through innovative stem cell therapies, by maintaining the largest, most diverse registry of donors, serve as a resource to physicians and patients, and conduct research to improve the outcomes of marrow and stem cell transplants. The NMDP has developed A Medical Professional's Guide to Unrelated Donor Stem Cell Transplants as an educational tool for oncologists, hematologist, geneticists, and other referring health professionals to learn about the process of searching for a donor and the importance of the timing of this search.
This guide provides information on advances in the outcomes of stem cell transplant, diagnoses that are treatable by transplant, the importance of initiating a donor search early in the disease process, statistical data on outcomes by disease type and timing of transplant, statistics on the diversity of available donors, and a listing of NMDP transplant centers and contacts. This guide is a valuable resource to healthcare professionals who provide care to patients with diseases treatable by stem cell transplantation. In light of the improved outcomes when transplants are done earlier in the disease course, many referring physicians discuss the option of transplant with patients at an earlier stage. The NMDP can provide the resources for physicians and patients to effectively discuss a patient's options. The Medical Professional's Guide to Unrelated Donor Stem Cell Transplantation is available for download, or you can order a copy via the online form found on the NMDP website.
Want to present this data to your colleagues? The NMDP has developed a PowerPoint slide presentation, including all materials found in the guide, available for download on their website.
Do you require more information for your patients? Or are you a patient who would like information on a more basic level? The NMDP has information on all aspects of transplant available on their website. In 1991, the NMDP formed the Office of Patient Advocacy to provide support and information to patients and families going through the donor search and transplant process. To speak to with a patient advocate, call 1-888-999-6743 (Spanish speaking advocates are also available).
Dr. Hill-Kayser talks about working in oncology care and how her line of work can be particularly rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

